

Substitute for form 1449B/PTO

**FIFTH SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
IN AN APPLICATION**

LISTING OF REFERENCES



MAY 15 2008

May 13, 2008

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
2907.1000-003APPLICATION NO.
10/686,943FIRST NAMED INVENTOR
Andrew McMichaelFILING DATE
October 16, 2003EXAMINER
Louise Humphrey, Ph.D.CONFIRMATION NO.
4585GROUP
1648**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
/L.H./	A7	2001/0036928 A1	11-01-2001	Chamberlain, et al.

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
/L.H./	B13	WO 99/41383 A1	08/19/1999	Maxygen, Inc.	
	B14	WO 02/24224 A2	03/28/2002	Oxxon Pharmaccines Limited	
	B15	WO 2005/026370 A2	03/24/2005	Aventis Pasteur Limited and Therion Biologics, Inc.	
	B16	WO 2006/061643 A1	06/15/2006	Oxxon Therapeutics Ltd.	
	B17	WO 2006/120474 A2	11/16/2006	Oxxon Therapeutics Ltd.	
	B18	WO 2006/125983 A1	11/30/2006	Oxxon Therapeutics Ltd.	
↓	B19	CN 1 324 661 A	12/05/2001	Second Military Medical University, PLA	X

EXAMINER /Louise Humphrey/

DATE CONSIDERED 07/02/2008

Substitute for form 1449B/PTO

FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION		ATTORNEY DOCKET NO. 2907.1000-003	APPLICATION NO. 10/686,943
LISTING OF REFERENCES May 13, 2008 (Use several sheets if necessary)		FIRST NAMED INVENTOR Andrew McMichael	FILING DATE October 16, 2003
		EXAMINER Louise Humphrey, Ph.D.	CONFIRMATION NO. 4585
			GROUP 1648

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/L.H./	AT9	SYFPEITHI Database, "Find Your Motif," [online], [retrieved on 2006-09-01]. Retrieved from the Internet <URL: http://www.syfpeithi.de/Scripts/MHCSERVER.dll/FindYourMotif.htm >.	
	AS10	The Schlom Declaration cited in the Notice of Opposition to a European Patent. Patent No.: EP0979284 [Date signed by Declarant: Sept. 24, 2003; Date signed by Opponent: Oct. 2, 2003; Date filed in EPO: Oct. 2, 2003]	
	AT10	The Gritz Declaration cited in the Notice of Opposition to a European Patent. Patent No.: EP0979284 [Date signed by Opponent: Oct. 2, 2003; Date filed in EPO: Oct. 2, 2003].	
	AU10	The Chamberlain Declaration cited in the Notice of Opposition to a European Patent. Patent No.: EP0979284 [Date signed by Opponent: Oct. 2, 2003; Date filed in EPO: Oct. 2, 2003]	
	C37	Notice of Opposition to a European Patent. Patent No.: EP 1 214 416. Opponent: Transgene S.A. (English translation attached.) [Date signed by Opponent: Feb. 3, 2006 ; Date filed in EPO: Feb. 6, 2006]	
	C38	Notice of Opposition to a European Patent. Patent No.: EP 1 214 416 B1. Opponent: Merck & Co., Inc. [Date signed by Opponent: Feb. 9, 2006 ; Date filed in EPO: Feb. 13, 2006]	
	C39	Notice of Opposition to a European Patent. Patent No.: EP 1 214 416 B1. Opponent: Crucell Holland B.V. [Date signed by Opponent: Feb. 6, 2006 ; Date filed in EPO: Feb. 13, 2006]	
	C90	Chow, Y-H., et al., "Improvement of Hepatitis B Virus DNA Vaccines by Plasmids Coexpressing Hepatitis B Surface Antigen and Interleukin-2," <i>J. Virol.</i> , 71(1): 169-178 (1997).	
	C91	Haigwood, N.L., "Predictive Value of Primate Models for AIDS," <i>AIDS Reviews</i> 6: 187-198 (2004).	
↓	C92	Hutchings, C.L., et al., "Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity," <i>J. Immunol.</i> , 175: 599-606 (2005).	

EXAMINER /Louise Humphrey/	DATE CONSIDERED 07/02/2008
-----------------------------------	-----------------------------------

Substitute for form 1449B/PTO

**FIFTH SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
IN AN APPLICATION**

LISTING OF REFERENCES

May 13, 2008

(Use several sheets if necessary)

ATTORNEY DOCKET NO. 2907.1000-003	APPLICATION NO. 10/686,943	
FIRST NAMED INVENTOR Andrew McMichael	FILING DATE October 16, 2003	
EXAMINER Louise Humphrey, Ph.D.	CONFIRMATION NO. 4585	GROUP 1648

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/L.H./	C93	Lindsey, K.R., <i>et al.</i> , "Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma," <i>Clin. Cancer Res.</i> , 12(8): 2526-2537 (2006).
	C94	Marshall, J.L., <i>et al.</i> , "Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti-Carcinoembryonic Antigen Immune Responses," <i>J. Clin. Oncol.</i> , 18(23): 3964-3973 (2000).
	C95	Rosenberg, S.A., <i>et al.</i> , "Recombinant Fowlpox Viruses Encoding the Anchor-Modified gp100 Melanoma Antigen can Generate Antitumor Immune Responses in Patients with Metastatic Melanoma," <i>Clin. Cancer Res.</i> , 9(8): 2973-2980 (2003).
	C96	Tagawa, S.T., <i>et al.</i> , "Phase I Study of Intranodal Delivery of a Plasmid DNA Vaccine for Patients with Stage IV Melanoma," <i>Cancer</i> , 98(1): 144-154 (2003).
	C97	Tomiyama, H., <i>et al.</i> , "Different Effects of Nef-Mediated HLA Class I Down-Regulation on Human Immunodeficiency Virus Type 1-Specific CD8 ⁺ T-Cell Cytolytic Activity and Cytokine Production," <i>J. Virol.</i> , 76(15): 7535-7543 (2002).
	C98	van Baren, N., <i>et al.</i> , "Tumoral and Immunologic Response After Vaccination of Melanoma Patients with an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells," <i>J. Clin. Oncol.</i> , 23(35): 9008-9021 (2005).
	C99	Vuola, J.M., <i>et al.</i> , "Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers," <i>J. Immunol.</i> , 174(1): 449-455 (2005).
	C100	Wang, X., <i>et al.</i> , "Cellular Immune Responses to Helper-Free HSV-1 Amplicon Particles Encoding HIV-1 gp120 are Enhanced by DNA Priming," <i>Vaccine</i> , 21(19-20): 2288-2297 (2003).
	C101	Woodberry, T., <i>et al.</i> , "Prime Boost Vaccination Strategies: CD8 T Cell Numbers, Protection, and Th1 Bias," <i>J. Immunol.</i> , 170: 2599-2604 (2003).
↓	C102	Zajac, P., <i>et al.</i> , "Phase I/II Clinical Trial of a Nonreplicative Vaccinia Virus Expressing Multiple HLA-A0201-Restricted Tumor-Associated Epitopes and Costimulatory Molecules in Metastatic Melanoma Patients," <i>Human Gene Therapy</i> , 14(16): 1497-1510 (2003).

EXAMINER /Louise Humphrey/	DATE CONSIDERED 07/02/2008
-------------------------------	-------------------------------